Oligoprogression in Non-Small Cell Lung Cancer
We reviewed the literature on oligoprogressive disease (OPD) and local ablative therapy (LAT) in patients with advanced non-small cell lung cancer (NSCLC). The frequency of OPD varies depending on its definition and is estimated to be between 15–47%. The implications of the strategy of continuing th...
Main Authors: | Daijiro Harada, Nagio Takigawa |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-11-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/22/5823 |
Similar Items
-
Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study
by: Chunhong Hu, et al.
Published: (2023-01-01) -
Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients
by: Pang-Shuo Perng, et al.
Published: (2023-11-01) -
Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments
by: Shanshan Chen, et al.
Published: (2023-03-01) -
Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?
by: Sviatoslav Chekhun, et al.
Published: (2023-12-01) -
The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma
by: Michele Guida, et al.
Published: (2019-10-01)